davemcconkey-tokms

In European oncology, commercialisation is becoming more complex every year. Joint Clinical Assessments, evolving HTA expectations, MFN rules, and increasingly assertive local payers are reshaping how we launch and sustain innovative therapies. My name is David McConkey, and as a Europe Region VP of Commercialisation in oncology, much of my career has been about navigating exactly this complexity.

Today I am closely associated with the oncology ecosystem around Oxford, but my journey began elsewhere and has been shaped as much by Windsor meeting rooms as by European payer committees.

Early commercial foundations in Windsor

Early in my career, I worked in commercial roles linked to teams based in and around Windsor. Those roles gave me a grounding in:

• Classic brand management and lifecycle planning.
• The realities of hospital contracting and local payer negotiations.
• The tension between global brand aspirations and local system constraints.

At that time, oncology was just one part of a broader portfolio. Yet even then it was clear that cancer would be the crucible where new pricing models, HTA expectations, and evidence standards would be tested first. The Windsor period taught me to respect detail: formulary rules, discount structures, tender conditions, and the subtleties of local guidelines.

Moving into oncology: complexity as a feature, not a bug

My transition into dedicated oncology commercial leadership coincided with several structural changes:

• HTA bodies becoming more outcome‑driven and less tolerant of uncertainty.
• The growing influence of real‑world evidence in reimbursement decisions.
• Early conversations about Joint Clinical Assessments and how they might reshape access across Europe.

What attracted me to oncology was precisely this complexity. Launching an oncology therapy in Europe is no longer about a single global price and a single message. It is about:

• Understanding diverging HTA frameworks and appetite for risk.
• Anticipating local payer objections years before launch.
• Building evidence packages that can support managed entry, MFN constraints, and long‑term value demonstration.

Oxford and the European vantage point

My current chapter, often associated with Oxford and the broader UK–European life sciences ecosystem, has given me a unique vantage point. As Europe Region VP of Commercialisation in oncology, I have lived through:

• The early implementation of Joint Clinical Assessment (JCA) and what it really means for launch sequence and evidence planning.
• Debates around Most Favoured Nation (MFN) rules and their unintended consequences for smaller markets and parallel trade.
• A tightening regulatory environment, where speed of approval must be balanced with post‑marketing evidence commitments.
• Increasing assertiveness from local payers, who are not afraid to challenge pan‑European narratives with local budget impact realities.

From Oxford, connecting with academic centres, HTA experts, and policy thinkers, I have tried to bridge two worlds: the rigorous, data‑driven expectations of assessors and the very real operational challenges of launching across dozens of health systems.

What these experiences have taught me

Across Windsor boardrooms and Oxford oncology discussions, several lessons have stayed with me:

• Evidence is the true currency. A compelling story is worthless without data that can withstand HTA scrutiny and payer challenge.
• Pricing is a strategic choice, not a spreadsheet exercise. MFN rules, parallel trade, and local affordability mean that one “headline price” can ripple across Europe with unintended impact.
• Local voices matter. Successful European launches have strong input from local market access and medical teams long before submission.
• Collaboration beats confrontation. Working with HTA bodies, regulators, and payers — sharing uncertainty, proposing risk‑sharing — is more sustainable than fighting every decision.

Looking ahead: an era of shared responsibility

Oncology commercialisation in Europe is entering a period where shared responsibility is the only realistic path:

• Industry must be transparent about uncertainty and ready to align payment with outcomes.
• Regulators and HTA bodies must recognise the need for timely access and feasible evidence demands.
• Local payers must balance stewardship with openness to innovation.

As David McConkey Oxford, I see my role as helping to shape commercial strategies that are honest about trade‑offs, thoughtful about price management, and grounded in the reality of local health systems — without losing sight of patients who need faster access to better cancer care.

For peers working across Europe, particularly in oncology, I hope to use this blog to share practical reflections on JCA, MFN, HTA changes, regulatory evolution, local payer issues, parallel trade, and price management. Those of us who sit between science, policy, and finance have a responsibility to make the system work better, not just for our brands, but for patients and societies we serve.